TY - JOUR
T1 - Multi-gene testing overview with a clinical perspective in metastatic triple-negative breast cancer
AU - Dameri, Martina
AU - Ferrando, Lorenzo
AU - Cirmena, Gabriella
AU - Vernieri, Claudio
AU - Pruneri, Giancarlo
AU - Ballestrero, Alberto
AU - Zoppoli, Gabriele
N1 - Funding Information:
This work was supported by an Italian Association for Cancer Research (AIRC) Investi-gator Grant (IG 21761) to GZ, Assocazione Italiana contro le leucemie (AIL) to AB and liberal donations.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/7/1
Y1 - 2021/7/1
N2 - Next-generation sequencing (NGS) is the technology of choice for the routine screening of tumor samples in clinical practice. In this setting, the targeted sequencing of a restricted number of clinically relevant genes represents the most practical option when looking for genetic variants associated with cancer, as well as for the choice of targeted treatments. In this review, we analyze available NGS platforms and clinical applications of multi-gene testing in breast cancer, with a focus on metastatic triple-negative breast cancer (mTNBC). We make an overview of the clinical utility of multi-gene testing in mTNBC, and then, as immunotherapy is emerging as a possible targeted therapy for mTNBC, we also briefly report on the results of the latest clinical trials involving immune checkpoint inhibitors (ICIs) and TNBC, where NGS could play a role for the potential predictive utility of homologous recombination repair deficiency (HRD) and tumor mutational burden (TMB).
AB - Next-generation sequencing (NGS) is the technology of choice for the routine screening of tumor samples in clinical practice. In this setting, the targeted sequencing of a restricted number of clinically relevant genes represents the most practical option when looking for genetic variants associated with cancer, as well as for the choice of targeted treatments. In this review, we analyze available NGS platforms and clinical applications of multi-gene testing in breast cancer, with a focus on metastatic triple-negative breast cancer (mTNBC). We make an overview of the clinical utility of multi-gene testing in mTNBC, and then, as immunotherapy is emerging as a possible targeted therapy for mTNBC, we also briefly report on the results of the latest clinical trials involving immune checkpoint inhibitors (ICIs) and TNBC, where NGS could play a role for the potential predictive utility of homologous recombination repair deficiency (HRD) and tumor mutational burden (TMB).
KW - Breast cancer
KW - Gene panels
KW - Metastatic triple-negative breast cancer
KW - Multi-gene testing
KW - Next-generation sequencing
KW - Tumor mutational burden
UR - http://www.scopus.com/inward/record.url?scp=85108867216&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85108867216&partnerID=8YFLogxK
U2 - 10.3390/ijms22137154
DO - 10.3390/ijms22137154
M3 - Review article
AN - SCOPUS:85108867216
VL - 22
SP - 7154
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
SN - 1661-6596
IS - 13
ER -